Pandion Therapeutics
Immunomodulating protein therapies for autoimmune disease treatment
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Founded
- 2016
- Latest Form D
- $21.6M, Jan 2018
- Total capital
- $21.6M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $21.6M
- 1 Form D · last Jan 2018
- 105 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 14 pending · first 2019
- Rank in peer group#293 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$21.6M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#293 · top 20%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alan CraneDirectorNamed in SEC Form D filings
- Anthony CoyleExecutive Officer, DirectorNamed in SEC Form D filings
- Carlo RizzutoDirectorNamed in SEC Form D filings
- Jo VineyExecutive OfficerNamed in SEC Form D filings
- Mitchell MutzDirectorNamed in SEC Form D filings
- Vikas GoyalDirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 18- PendingTargeted ImmunotoleranceUSPTOApplication 17053979
- GrantedIL-2 Muteins And Uses ThereofUSPTOUS 10,946,068
- GrantedTargeted ImmunotoleranceUSPTOUS 10,676,516
Show all 18 patent records
- Targeted ImmunotoleranceSep 9, 2021 · Application 17053979Pending
- IL-2 Muteins And Uses ThereofMar 16, 2021 · US 10,946,068Granted
- Targeted ImmunotoleranceJun 9, 2020 · US 10,676,516Granted
- IL-2 Muteins And Uses ThereofJun 6, 2019 · Application 16229133Pending
- IL-2 Muteins And Uses ThereofJun 6, 2019 · Application 16229090Pending
- IL-2 MuteinsJan 8, 2019 · US 10,174,091Granted
- IL-2 MuteinsJan 8, 2019 · US 10,174,092Granted
- Targeted Immunotolerance With A PD-1 AgonistApplication 63027449Pending
- Targeted ImmunotoleranceApplication PCTUS2018062780Pending
- Targeted ImmunotoleranceApplication 62732684Pending
- IL-2 Muteins And Uses ThereofApplication 62721644Pending
- Targeted ImmunotoleranceApplication PCTUS2018034334Pending
- Tissue Targeted Immunotolerance With PD-1 Agonists Or IL-2 MuteinsApplication 62979859Pending
- Targeted ImmunotoleranceApplication PCTUS2018022675Pending
- Targeted Immunotolerance With A PD-1 AgonistApplication 62888694Pending
- MAdCAM TARGETED IMMUNOTOLERANCEApplication 62850172Pending
- Targeted ImmunotoleranceApplication 62816450Pending
- IL-2 Muteins And Uses ThereofApplication PCTUS2018062808Pending
Related companies, and why
- Ra PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- Onconetix, Inc.Similar federal contract value in Biotech · null in contracts
- Culture Biosciences Inc.Similar federal contract value in Biotech · null in contracts
- LumaCyte, Inc.Similar federal contract value in Biotech · null in contracts
- Surface Ophthalmics, Inc.Similar federal contract value in Biotech · null in contracts
- MethylGene Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .